Generex launches commercial sales of oral insulin in Lebanon

Dubai Health and News

During a recent press conference in Beirut, Lebanese Minister of Health H.E. Muhammad Jawad Khalifah along with Generex Biotechnology Corporation and the company's sales sub-licensee and distributor for Lebanon, Bental s.a.l., announced the launch of commercial retail sales of Generex Oral-lyn in Lebanon.

The product has been approved for importation and commercial marketing and sale in Lebanon by the Ministry of Public Health, and will be marketed and sold for the treatment of patients with Type-1 and Type-2 diabetes.

Generex Oral-lyn™, Generex's proprietary oral insulin spray product, is the first non-injectable insulin approved in Lebanon. Generex Oral-lyn™ is delivered via the Company's proprietary RapidMist™ device into the mouth. Unlike inhaled insulin products, buccally absorbed Generex Oral-lyn™ does not reach the lungs.

The launch of Generex Oral-lyn™ took place at Le Royal Hotel, Dbayeh on May 14th. In addition to more than 150 endocrinologists and other healthcare providers in attendance, notable participants included:

• H.E. Dr. Mohamad Jawad Khalifah, Minister of Health, Lebanon

• Mr. Bernard Tannoury, Chairman and CEO of Benta s.a.l.

• Mr. Bill Abajian, Sr. Executive Advisor, Global Licensing and Business Development, Generex Biotechnology corporation

• Professor Paolo Pozzilli, Head of the Department of Diabetes and Endocrinology, University Campus Bio-Medico, Rome, Italy

• Professor Sami Azar, M.D., FACP, The Department of Internal Medicine (Endocrinology), Faculty of Medicine, American University of Beirut - Medical Center, Beirut, Lebanon

"It is with great enthusiasm that we launch Generex Oral-lyn™ in Lebanon alongside Benta s.a.l., known for their leading edge innovation," said Anna Gluskin, Generex's Chairman & Chief Executive Officer. "We anticipate that our truly innovative product will be well received and expand further into the Middle East over the coming year as we pursue our regulatory program."

Generex is a biotechnology company engaged in the research, development and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, oral insulin (Generex Oral-lyn™, which is now available for sale in several Middle Eastern countries for the treatment of patients with Type-1 and Type-2 diabetes, and is in Phase III clinical trials at several sites around the world.